Towards a molecular therapy for glycogen storage disease type II (Pompe disease). (Q33935462)

30 July 2017

1 reference

title

Towards a molecular therapy for glycogen storage disease type II (Pompe disease). (English)

1 reference

30 July 2017

main subject

glycogen storage disease

1 reference

Chen YT

1 reference

30 July 2017

Amalfitano A

series ordinal

1 reference

30 July 2017

publication date

1 June 2000

1 reference

Trends in Molecular Medicine

30 July 2017

1 reference

inferred from page(s)

published in

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

245-251

1 reference

Glycogenosis type II (acid maltase deficiency)

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Improvement of muscle function in acid maltase deficiency by high-protein therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Intracellular transport of acid alpha-glucosidase in human fibroblasts: evidence for involvement of phosphomannosyl receptor-independent system

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Recombinant proteins for genetic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNA oligonucleotides. Targeted delivery of liposomes and polyethyleneimine to the asialoglycoprotein receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Retroviral Transfer of Acidα-Glucosidase cDNA to Enzyme-Deficient Myoblasts Results in Phenotypic Spread of the Genotypic Correction by Both Secretion and Fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

The fate of individual myoblasts after transplantation into muscles of DMD patients

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Muscle regeneration by bone marrow-derived myogenic progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

Dystrophin expression in the mdx mouse restored by stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2800%2901694-4

7 January 2021

10.1016/S1357-4310(00)01694-4

Identifiers

DOI

1 reference

30 July 2017

1 reference